A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: A Single-Arm Clinical Trial of Feasibility

被引:3
|
作者
Petoe, Matthew A. [1 ]
Abbott, Carla J. [2 ,3 ,4 ]
Titchener, Samuel A. [1 ]
Kolic, Maria [3 ]
Kentler, William G. [5 ]
Nayagam, David A. X. [1 ,3 ,6 ]
Baglin, Elizabeth K. [3 ]
Kvansakul, Jessica [1 ]
Barnes, Nick [7 ]
Walker, Janine G. [7 ,8 ]
Karapanos, Lewis [3 ,4 ,9 ]
McGuinness, Myra B. [3 ,4 ]
Ayton, Lauren N. [3 ,4 ]
Luu, Chi D. [3 ,4 ]
Allen, Penelope J. [3 ,4 ,10 ]
机构
[1] Bion Inst, Melbourne, Vic, Australia
[2] Univ Melbourne, Med Dept Bion, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia
[6] Univ Melbourne, St Vincents Hosp, Dept Pathol, Melbourne, Vic, Australia
[7] Australian Natl Univ, Res Sch Engn, Canberra, ACT, Australia
[8] CSIRO, Hlth & Biosecur, Canberra, ACT, Australia
[9] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Australia
[10] Royal Victorian Eye & Ear Hosp, Vitreoretinal Unit, Melbourne, Australia
来源
OPHTHALMOLOGY SCIENCE | 2025年 / 5卷 / 01期
基金
英国医学研究理事会;
关键词
Suprachoroidal retinal prosthesis; Functional vision; Bionic eye; Retinitis; pigmentosa; QUALITY-OF-LIFE; FUNCTIONAL VISION; BLIND SUBJECTS; VISUAL PERFORMANCE; SYSTEM; PART;
D O I
10.1016/j.xops.2024.100525
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess the feasibility of a second-generation (44-channel) suprachoroidal retinal prosthesis for provision of functional vision in recipients with end-stage retinitis pigmentosa (RP) over 2.7 years. Design: Prospective, single-arm, unmasked interventional clinical trial. Participants: Four participants, with advanced RP and bare-light perception vision. Methods: The 44-channel suprachoroidal retinal prosthesis was implanted in the worse-seeing eye. Device stability, functionality, and adverse events were investigated at approximately 12-week intervals up to 140 weeks (2.7 years) postdevice activation. Main Outcome Measures: Serious adverse event (SAE) reporting, visual response outcomes, functional vision outcomes, and quality-of-life outcomes. Results: All 4 participants (aged 39-66 years, 3 males) were successfully implanted in 2018, and there were no device-related SAEs over the duration of the study. A mild postoperative subretinal hemorrhage was detected in 2 recipients, which cleared spontaneously within 2 weeks. OCT confirmed device stability and position under the macula. Improvements in localization abilities were demonstrated for all 4 participants in screen-based, tabletop, and orientation and mobility tasks. In addition, 3 of 4 participants recorded improvements in motion discrimination and 2 of 4 participants recorded substantial improvements in spatial discrimination and identification of tabletop objects. Participants reported their unsupervised use of the device included exploring new environments, detecting people, and safely navigating around obstacles. A positive effect of the implant on participants' daily lives in their local environments was confirmed by an orientation and mobility assessor and participant self-report. Emotional well-being was not impacted by device implantation or usage. Conclusions: The completed clinical study demonstrates that the suprachoroidal prosthesis raises no safety concerns and provides improvements in functional vision, activities of daily living, and observer-rated quality of life. (c) 2024 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页数:17
相关论文
共 49 条
  • [41] Feasibility, acceptability and preliminary clinical outcomes of a brief coping-focused intervention for delusions blended with smartphone-based ecological momentary assessment and intervention in persons with schizophrenia spectrum disorders: A pilot single-arm trial
    Boege, Kerem
    Bergmann, Niklas
    Hahne, Inge
    Emde, Laura
    Cartner, Sharla
    Bell, Imogen
    Pillny, Matthias
    Thomas, Neil
    INTERNET INTERVENTIONS-THE APPLICATION OF INFORMATION TECHNOLOGY IN MENTAL AND BEHAVIOURAL HEALTH, 2025, 39
  • [42] Impacto - A single-arm open-label pilot trial of a digital-based integrated smoking cessation program for Spanish-speaking Hispanic individuals who smoke: Development, feasibility, engagement, and clinical outcomes
    Zvolensky, Michael J.
    Brown, Richard A.
    Shepherd, Justin M.
    Brown, Jason T.
    Redmond, Brooke Y.
    Alcocer, Sergio
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2025, 170
  • [43] Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK plus NSCLC
    Stinchcombe, Thomas E.
    Doebele, Robert C.
    Wang, Xiaofei
    Gerber, David E.
    Horn, Leora
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : 156 - 161
  • [44] A single-arm, open phase II clinical trial of anti programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson's disease without cognitive impairment
    Shepherd T.A.
    Edelstyn N.M.J.
    Longshaw L.
    Sim J.
    Watts K.
    Mayes A.R.
    Murray M.
    Ellis S.J.
    Pilot and Feasibility Studies, 4 (1)
  • [46] A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
    Chen, Can
    Chen, Minjun
    Bai, Yuju
    Li, Yajun
    Peng, Jie
    Yao, Biao
    Feng, Jiangping
    Zhou, Jian-Guo
    Ma, Hu
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [47] Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial
    Jiang, X.
    Li, M.
    Jiang, R.
    Huang, C.
    Huang, D.
    Chen, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S874 - S874
  • [48] Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naive Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial
    Lin, Jinghui
    Li, Meifang
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 2557 - 2567
  • [49] A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study
    Maeda, Hiromichi
    Nagata, Naoki
    Nagasaka, Takeshi
    Oba, Koji
    Mishima, Hideyuki
    Kato, Takeshi
    Yoshida, Kazuhiro
    Muro, Kei
    Sakamoto, Junichi
    ONCOLOGY LETTERS, 2019, 17 (02) : 1980 - 1985